2024
Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab
Bewersdorf J, Hasle V, Shallis R, Thompson E, De Menezes D, Rose S, Boss I, Mendez L, Podoltsev N, Stahl M, Kewan T, Halene S, Haferlach T, Fox B, Zeidan A. Immune Landscape and Outcomes of Patients with RNA Splicing Factor-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes Treated with Azacitidine +/- the Anti-PD-L1 Antibody Durvalumab. Blood 2024, 144: 4585. DOI: 10.1182/blood-2024-194929.Peer-Reviewed Original ResearchAcute myeloid leukemiaAnti-PD-L1 antibody durvalumabOverall response rateMyelodysplastic syndromeComplete responseBM aspiratesMyeloid leukemiaInternational Working GroupBone marrowMyelodysplastic syndromes treated with azacitidineAcute myeloid leukemia ptsWild-type acute myeloid leukemiaSecondary acute myeloid leukemiaResponse criteriaAnti-PD-L1Immune checkpoint inhibitorsTreated with azacitidineOutcomes of patientsAny-cause deathGeneration of neoantigensVariant allele frequencySusceptible to treatmentMarrow CRAdverse cytogeneticsCheckpoint inhibitors
2021
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Horvat T, Abdel-Wahab O, Levine R, Viny A, Stein E, Cai S, Roshal M, Tallman M, Goldberg A. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances 2021, 5: 1552-1564. PMID: 33687434, PMCID: PMC7948282, DOI: 10.1182/bloodadvances.2020003734.Peer-Reviewed Original ResearchConceptsLow-dose cytarabineAcute myeloid leukemiaMolecular predictors of responseRR-AMLPredictors of responseHigh response rateVenetoclax therapyOverall survivalResponse rateMolecular predictorsAssociated with higher response ratesMorphologic leukemia-free stateAllogeneic stem cell transplantationAssociated with worse OSRefractory acute myeloid leukemiaRelapsed/refractory acute myeloid leukemiaEvaluate novel agentsIncomplete hematologic recoveryMedian overall survivalVenetoclax combination therapyStem cell transplantationOverall response rateAcquisition of novel mutationsVenetoclax combinationsAdverse cytogenetics
2020
Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King A, Daniyan A, Famulare C, Cuello B, Abdel-Wahab O, Levine R, Viny A, Stein E, Roshal M, Tallman M, Goldberg A. Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood 2020, 136: 47-48. DOI: 10.1182/blood-2020-137815.Peer-Reviewed Original ResearchCurrent equity holderEntity's Board of DirectorsRR-AMLRR-AML patientsMeasurable residual diseaseOverall survivalCombination therapyVenetoclax therapyAdverse cytogeneticsComplete responseResponse rateMedian OSRefractory AMLResidual diseaseEuropean LeukemiaNetMolecular predictorsClinical outcomesADC therapeuticsAssociated with prolonged OSCycle 1 day 1Venetoclax-based combination therapiesAllogeneic stem cell transplantationLevel of residual diseaseAssociated with poor OSMemorial Sloan Kettering Cancer Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply